The Outer Membrane Proteins OmpA, CarO, and OprD of Acinetobacter baumannii Confer a Two-Pronged Defense in Facilitating Its Success as a Potent Human Pathogen

Siva R. Uppalapati, Abhiroop Sett and Ranjana Pathania*

Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India

Of all the ESKAPE pathogens, carbapenem-resistant and multidrug-resistant Acinetobacter baumannii is the leading cause of hospital-acquired and ventilator-associated pneumonia. A. baumannii infections are notoriously hard to eradicate due to its propensity to rapidly acquire multitude of resistance determinants and the virulence factor cornucopia elucidated by the bacterium that help it fend off a wide range of adverse conditions imposed upon by host and environment. One such weapon in the arsenal of A. baumannii is the outer membrane protein (OMP) compendium. OMPs in A. baumannii play distinctive roles in facilitating the bacterial acclimatization to antibiotic- and host-induced stresses, albeit following entirely different mechanisms. OMPs are major immunogenic proteins in bacteria conferring bacteria host-fitness advantages including immune evasion, stress tolerance, and resistance to antibiotics and antibacterials. In this review, we summarize the current knowledge of major A. baumannii OMPs and discuss their versatile role in antibiotic resistance and virulence. Specifically, we explore how OmpA, CarO, and OprD-like porins mediate antibiotic and amino acid shuttle and host virulence.

Keywords: OmpA, CARO, OprD, antibiotic resistance, virulence

INTRODUCTION

The Gram-negative coccobacillus Acinetobacter baumannii is an aerobic opportunistic pathogen responsible for some of the most morbid hospital-acquired infections (Bouvet and Grimont, 1987; Peleg et al., 2008; Lin and Lan, 2014; Lee et al., 2017). The global threat from this pathogen comes from its high rate of resistance gene acquisition leading to rapid emergence of multidrug-resistant (MDR) clinical isolates (Abbott et al., 2013; Giammanco et al., 2017; Rodloff and Dowzicky, 2017). Increasing number of studies show frequent isolation of carbapenem and colistin-resistant strains of A. baumannii from clinical settings (Garnacho-Montero et al., 2005; Asadollahi et al., 2012; Zhao et al., 2015; Benmahmod et al., 2019; Pormohammad et al., 2020). Swift accumulation and dispersion of antibiotic resistance markers along with the ability to cause urinary tract infections, skin and soft tissue infections and wound infections (Sievert et al., 2013;
Weiner et al., 2016; Giammanco et al., 2017) makes A. baumannii, a pathogen of great significance for both humans and animals (Sen and Joshi, 2016; van der Kolk et al., 2019). In light of this, the World Health Organization (WHO) categorized this organism as a priority-1 critical pathogen for which discovery of new treatment options is of utmost importance (World Health Organization [WHO], 2017). The potency of A. baumannii as a successful pathogen can be elaborated by the high number of deaths associated with its infection. A recent finding showed that bacteremia caused by multidrug-resistant (MDR) A. baumannii exhibited 56.2% mortality rate among infected patients (Zhou et al., 2019).

A plethora of virulence factors are elucidated by A. baumannii (Harding et al., 2018), some of which include, but are not limited to, porin proteins, efflux pumps, outer membrane vesicles, metal acquisition systems, secretion systems, phospholipases, and capsular polysaccharides (Lee et al., 2017; Sharma et al., 2019; Skarichychan et al., 2019). Recent advances in research have not only provided better knowledge of these determinants, but also shed light on how these can be used as potential drug targets (Bhattacharyya et al., 2017; Iyer et al., 2018). However, growth conditions like temperature, oxygen content, osmolarity, and media components regulate the expression of porins in A. baumannii (Hwa et al., 2010; Fernando and Kumar, 2012; Baizyaleu and Kumar, 2014). Transcriptional and post-transcriptional regulatory networks (Kuo et al., 2017; Sharma et al., 2018) also determine the virulence and antibiotic resistance of A. baumannii.

Among the vast diversity of antibiotic resistance and virulence determinants and A. baumannii specific regulatory networks, one group of bacterial proteins, termed outer membrane proteins (OMPs) due to their localization, have been studied with utmost interest due to their distribution, functional relevance and stipulated role in both antibiotic resistance and virulence (Sato et al., 2017; Nie et al., 2020). OMPs in general are beta barrel-shaped monomeric or trimeric porins (Table 1) that allow diffusion of small molecules into and out of periplasmic space of Gram-negative bacteria (Nitzan et al., 1999; Nikaido, 2003; Slusky and Dunbrack, 2013). A. baumannii outer membrane holds scores of OMPs including OmpA, CarO, OprD-like OMPs, Omp 33-36 kDa, AbuO, TolB, DcaP, Oma87/BamA, NmrRmpM, CadE, OprF, etc. (Borneleit and Kleber, 1991; Park et al., 2012; Srinivasan et al., 2015; Lee et al., 2017; Bhamidimarri et al., 2019; Rasooli et al., 2020). OMPs participate in a wide range of functions that assist the bacterium in enduring the harsh environmental conditions, in combating the threat posed by antimicrobial compounds (Limasky et al., 2002; del Mar Tomás et al., 2005; Dupont et al., 2005; Mussi et al., 2007; Choi et al., 2008a; Srinivasan et al., 2015; Wang et al., 2015), host (Choi et al., 2008b,c; Lee et al., 2008; Gaddy, 2010), and surprisingly, in degrading crude oil (Hanson et al., 1994). Immunization with A. baumannii OMPs ensued significant rise in protective immune parameters (McConnell et al., 2011; Alzubaïdi and Alkozai, 2015; Bazmara et al., 2019) and antibodies against OMPs passively protected experimental animals (Goel and Kapil, 2001). Clinical studies frequently identify differential expression of OMPs in antibiotic resistant A. baumannii strains, establishing their role in conferring resistance (Cuenca et al., 2003; Yun et al., 2008; Vashist et al., 2010; Moganty et al., 2011; Mostachio et al., 2012).

Here, we explore and summarize how antibiotic resistance and virulence in A. baumannii is mediated by different OMPs like OmpA, CarO and OprD.

### OmpA

OmpA, a beta barrel-shaped monomeric protein (Park et al., 2011) is one of the most abundant OMPs (Gribun et al., 2003), which has been reported to impart drug resistance to A. baumannii by allowing slower diffusion of negatively charged beta-lactam antibiotics (Nitzan et al., 2002) and virulence (Sato and Nakae, 1991; Sato et al., 2017; Sánchez-Encinales et al., 2017) by its toxicity to host cells. Clinical isolates of A. baumannii overexpressing OmpA arbitrate higher morbidity and even mortality in patients (Sato et al., 2017; Sánchez-Encinales et al., 2017). The global repressor H-NS binds to the promoter region of OmpA gene and gene locus A1S_0316 and the two component system BfmSR function as a possible anti-repressor and repressor of OmpA in A. baumannii, respectively (Liou et al., 2014; Oh et al., 2020).

### Role of OmpA in Antibiotic Resistance in A. baumannii

Being the most abundant porin in A. baumannii, the role of OmpA in antibiotic resistance was more prominent in disruption mutants of the gene, which showed increased susceptibility to nalidixic acid, chloramphenicol, aztreonam, imipenem, and meropenem. Besides diffusion, research indicates that OmpA possibly couples with efflux pumps and forces out antibacterial compounds from the periplasm (Smani et al., 2013; Fahmy et al., 2018; Tsai et al., 2020). OmpA also couples to A. baumannii peptidoglycan (PG) via its C-terminal region, where Asp271 and Arg286 bind to dianimopimelic acid of PG (Park et al., 2012). This binding may regulate outer membrane vesicle (OMV) production and the membrane stability in the bacteria (Moon et al., 2012). OMVs with OmpA in their membrane (Walzer et al., 2006; Jin et al., 2011; Yun et al., 2018) mediate antibiotic resistance by actively siphoning extracellular drugs (Agarwal et al., 2019). Recently, resistance to colistin, a last-resort antibiotic, was also attributed to the presence of OmpA in A. baumannii. An isogenic mutant of OmpA resulted in loss of cell wall integrity, thus making the bacterium 20-fold more sensitive to colistin (Kwon et al., 2019) and 5.3 fold more sensitive to trimethoprim (Kwon et al., 2017) than wild type A. baumannii. The distinctive role of OmpA in conferring antibiotic resistance thrusts researchers to discover novel antibacterials against the protein. In one study, a novel diazabicyclooctenone beta-lactamase inhibitor that inhibits major classes of carbapenemases and in turn potentiates sulbactam activity was shown to be OmpA-dependent (Iyer et al., 2018). OmpA blockers can function synergistically with last resort antibiotics like colistin in eradicating MDR strains of A. baumannii (Vila-Farrés et al., 2017; Parra-Millán et al., 2018). OmpA also interacts with antimicrobial peptides (AMPs) of diverse origin and confers resistance against them (Lin et al., 2015; Guo Y. et al., 2018). Minimum inhibitory
concentrations of human AMP LL-37 and bovine AMP BMAP-28 increased upon binding to N-terminal region of OmpA. The multifaceted role of OmpA in A. baumannii membrane permeability and cell wall integrity indicates its potential as a candidate for novel antibacterial development via chemical genetic screens.

Role of OmpA in A. baumannii
Adherence and Invasion of Host Cells

Besides their distinguishable role in antibiotic resistance, OMPs confer virulence to A. baumannii. The bacterium is capable of invading and persisting in host epithelial and immune cells (Figure 1). The primary requisite for invasion is to adhere to the host cells, which is mediated by many virulence factors expressed by A. baumannii viz., OmpA (Nie et al., 2020), BapA (Brossard and Campagnari, 2012), fimbrial like protrusions (Mortensen and Skaar, 2012). A. baumannii adherence to host cells can be both host cell and bacterial sequence-type specific. For instance, two types of adherence patterns have been elucidated in A. baumannii; dispersed adherence of bacteria to the host cells, and adherence of clusters of bacteria at localized areas of the host cells (Lee et al., 2006). Bacterial clusters can be a result of amyloidogenic BAP protein mediated biofilm formation. Interestingly, OmpA specifically mediates bacterial binding to healthy cells than cancerous cells (Choi et al., 2008c). A. baumannii cells devoid of OmpA were found to be less virulent to human airway epithelium due to decreased adherence to cells (Gaddy, 2010) and formed weaker biofilms (Gaddy et al., 2009; Lin et al., 2020).

Following adherence to host cells, A. baumannii invades into the cell cytoplasm. The bacterial penetration into epithelial cells is microfilament- and microtubule-dependent following zipper-like mechanism (Choi et al., 2008c). Upon internalization, A. baumannii cells localize to membrane-bound vacuoles and finally traffic to the nucleus. Bacterial cells actively divide and finally kill the host cell to release into the blood stream. In this process, OmpA actively assists bacterial invasion, although by unknown mechanisms (Kim et al., 2016). Iron homeostasis is found to be a key factor regulating the survival of A. baumannii in the cytoplasm (Gaddy, 2010). Other adherence factors like BapA are not found to mediate invasion of A. baumannii (Brossard and Campagnari, 2012; De Gregorio et al., 2015) indicating that OmpA specific pathways regulate A. baumannii virulence. The functional dynamics of such a feature for a protein can be emphasized succinctly by looking into immune responses in the host.

Immune Response Configuration Against A. baumannii OmpA

In healthy individuals, A. baumannii cells in the blood stream and airways are actively phagocytosed by circulatory or tissue-resident immune cells like macrophages, neutrophils, dendritic cells (DCs), etc. (Harding et al., 2018) before leading to fulminant A. baumannii sepsis, although the latter is the case frequently encountered in immunocompromised patients. A. baumannii induces host cell cytotoxicity by targeting mitochondrial system and nuclear localization. In epithelial cells, OmpA induces the surface expression of Toll-like receptor 2 and the production of inducible nitric oxide synthase (Kim et al., 2008). Phagocytosed bacteria release several structural and cytoplasmatic proteins that induce cytotoxicity directly (e.g., Type VI secretion system effector enzymes, and toxins) or indirectly by activating caspases (e.g., OmpA). In macrophages and epithelial cells, OmpA triggers autophagy, albeit incomplete, by preventing the fusion of autophagosomes with lysosomes, activating MAPK/JNK signaling pathway (Kim et al., 2008; An and Sü, 2019) and enhancing the levels of phosphorylated JNK, p38, ERK and c-Jun (An et al., 2019). Early response in DCs treated with OmpA includes augmenting the expression of CD40, CD54, CD80, CD86 and MHC-I and II surface markers. The marker expression is accompanied by
FIGURE 1 | Function of major OMPs in A. baumannii. Five major OMPs with their substrate specificity is shown. OmpA porin mediates uptake of \( \beta \)-lactam and colistin antibiotics. Human antimicrobial peptide LL-37 and bovine AMP BMAP-28 may bind to the porin. OmpA pore size is optimal for uptake of iron siderophores like acenotobactin. A coiled loop in the C-terminal region of the protein binds to peptidoglycan maintaining the membrane integrity. Phagocytosed A. baumannii releases OmpA into the cytoplasm of host cells. Secreted OmpA inhibits lysosome fusion to autophagosomes, enters into mitochondria inducing ROS generation. Secreted OmpA actively localizes to nucleus via nuclear pore complex where it activates apoptotic markers like caspases. Ab, A. baumannii; OM, outer membrane; PG, peptidoglycan; IM, inner membrane; sOmpA, secreted OmpA; ROS, reactive oxygen species.

secretion of Th-1 promoting IL-12 (Lee et al., 2007). However, upon prolonged exposure, secreted OmpA in DCs targets mitochondria and induces production of reactive oxygen species (ROS) (Lee et al., 2008 and 2010). ROS stimulates early-onset apoptosis and delayed-onset necrosis in DCs, thus impairing T-cell response against A. baumannii. Besides induction of ROS,
OmpA in conjunction with carbolic anhydrase IX stimulates DCs to generate potent anti-tumor immune response against renal cell carcinoma (Kim B.R. et al., 2011; Kim D.Y. et al., 2011; Kim et al., 2012).

All these observations in the host indicate that OmpA might be toxic in nature, unlike other outer membrane proteins. The toxicity of A. baumannii OmpA can be attributed to its unique structural features and vast diversity of alleles (Viale and Evans, 2020) with conserved domains. OmpA protein is comprised of two domains; an N-terminal 8-stranded β-barrel domain and a C-terminal periplasmic peptidoglycan binding domain. OmpA possesses a basic amino-acid rich signal termed nuclear localization signal (NLS) ‘KTKEGRAMNR’ (Choi et al., 2007) on its C-terminal domain. Karyopherin β family proteins on nuclear pore complex recognize the NLS via its lysine (K) residues and shuttle OmpA to nucleus from cytoplasm. It can thus be speculated that OmpA devoid of NLS can be a non-toxic variant. Studies to reduce the host cell toxicity of recombinant A. baumannii revealed the importance of both N and C-terminal regions and the importance of lysine residues in NLS sequence. A synthetic OmpA with mutations at K320 and K322 to Alanine, replacing “NADEEFWN” sequence with “YKYDFDGVRNGTRGGEGLTL” and deleting N-terminal signal sequence and “VQVPGQEAAPQ” at C-terminal resulted in least toxic but highly immunogenic OmpA (Jahangiri et al., 2017). In addition to NLS, the N-terminal region of OmpA is bioinformatically predicted to be more immunogenic (Darbandian and Sefid, 2016). The epitopes “QIQDSEHSGKMVAKRQ” at position 100–115 and “HTSFDKLPEGGRAT” at position 125–138 are delineated best by Ellipro software. A peptide at N-terminal region located at 24–50 position, “VTVPILLGLYTQFDSDLRHNGKGDGLNT” alone is immunogenic and elicited similar levels serum antibodies like OmpA (Mehdinejadiani et al., 2019). It is clear that OmpA is toxic to host when secreted and when intact, it provides antibiotic resistance to the bacterium. Whether these observations can be implied to the clinical manifestations of A. baumannii is yet to be elucidated.

**CarO**

Carbenem susceptibility porin or CarO was first reported in imipenem (IMP) sensitive A. baumannii isolates that acquired resistance upon the loss of a 29 kDa protein (Limansky et al., 2005). CarO is an 8-stranded beta barrel-shaped outer membrane channel protein that does not have a continuous channel (Mussi et al., 2005; Lee et al., 2011; Ravasi et al., 2011; Kim and Ko, 2015; Khorsi et al., 2018; Mirshekar et al., 2018). When exposed to a high concentration of monovalent cations like NaCl and KCl in vitro may not help eradicate A. baumannii infection from within the host system, especially in the case of urinary tract infections where there is the presence of a high concentration of monovalent cations like NaCl and KCl (Hood et al., 2010).

The recent identification that CarO is significantly up-regulated in an Hfq deletion mutant strain of A. baumannii indicate that it is kept under post-transcriptional control by the bacterium to regulate its expression in response to the changing environment (Kuo et al., 2017). Finally, the occasional isolation of antibiotic resistant strains with a loss of CarO gene signifies the diversity of resistance mechanisms in A. baumannii (Li et al., 2015). In contrast to these studies linking carbenem resistance to the loss of CarO, there are a few reports of the presence of CarO porin on the OM of carbapenem resistant clinical isolates of A. baumannii. However, this can possibly be explained by the “porin-localized toxin inactivation” model, where carbapenemases like Oxa-23 interact with the periplasmic region of OMPs like CarO or OmpA to act as an efficient selective filter to inactivate incoming antibacterial compounds (Li et al., 2015; Wu et al., 2016; Roey et al., 2018).

The clinical relevance of CarO has also been ascertained by many hospital epidemiological studies. These revealed that there is a prevalence of CarO deficiency amongst carbapenem resistant isolates expressing BlaOXA (Pajand et al., 2013; Abbasi et al., 2020) and TEM-1 (Nan et al., 2018) genes among the hospital isolates of A. baumannii. Various carbapenem resistant clinical isolates demonstrated a disruption in the CarO gene by insertion sequences like ISAba1, ISAba125, ISAba825, ISAba10, ISAba15, and ISAba36 (Mussi et al., 2005; Lee et al., 2011; Ravasi et al., 2011; Kim and Ko, 2015; Khorsi et al., 2018; Mirshekar et al., 2018). The immunological role of CarO protein in A. baumannii is studied inadequately. Sato et al. (2017) showed that clinical A. baumannii isolates expressing higher CarO mRNA levels negatively regulated TNF-α, IL-6 and IL-8 in lung epithelial cells. Recently, CarO has been linked to A. baumannii adhesion and virulence in host cells via inhibition of NF-kβ signaling (Zhang et al., 2019). However, the significance of this observation is debatable as the strain used in the study is ATCC 19606 where expression of CarO is significantly lesser than that of clinical strains (Sato et al., 2017).
OprD

OprD was first identified during outer membrane investigations of carbapenem resistant *A. baumannii* isolates (Dupont et al., 2005). It is an orthologous protein to a porin involved in the basic amino acid and imipenem transport in *Pseudomonas aeruginosaa* (Hancock and Brinkman, 2002). Crystallographic studies of a conserved *P. aeruginosaa* OprD revealed a monomeric 18-stranded β-barrel structure characterized by a very narrow pore constriction (Biswas et al., 2007). The amino acid conservation at structural domains between *A. baumannii* and *P. aeruginosaa* OprD porins indicate its putative function in *A. baumannii*. However, sequence and homology analysis of *A. baumannii* OprD showed that it belongs to *P. aeruginosaa* OprQ, a protein involved in resisting low-iron or magnesium and low oxygen stresses (Catel-Ferreira et al., 2012). Recombinant *A. baumannii* OprD did not conduct antibiotics but partially bound to Fe$^{3+}$ and Mg$^{2+}$ cations. An isogenic deletion mutant of *A. baumannii* OprD did not affect MICs of β-lactams (Smani and Pachón, 2013), but in *A. baylyi* spp., a significant reduction in MIC of imipenem, ertapenem and meropenem is observed (Morán-Barrio et al., 2017). Despite these two heralding reports on lack of relationship between OprD and antibiotic resistance in *A. baumannii*, single nucleotide polymorphisms and insertional elements in OprD have been frequently identified in MDR *A. baumannii* signifying its role in resistance. For instance, Yang et al., 2015; Liu et al., 2016 and Lai et al., 2018 showed SNP clusters in OprD in MDR and tigecycline-resistant *A. baumannii*, respectively. Downregulation of OprD was observed in MDR (Asai et al., 2014) and pan drug-resistant (Cuenca et al., 2011) *A. baumannii* clinical strains. Insertion of mobile element ISAba1 upstream to the gene was also associated with increased carbapenem MICs of *A. baumannii* sequence type 107 strains (Costa et al., 2019). OprD was renamed to OccAB1 by Zahn et al. (2016), while solving its crystal structure. In their work, Zahn et al., resolved structures of four carboxylate channels OccAB1, 2, 3, and 4 and showed that OccAB1 has the largest channel size with corresponding high rates of small-molecule shuttle, including amino acids, sugars, and antibiotics, contrary to previous observations. The particularly large pore size of OccAB1 facilitates the objective translocation of both positive and negative substrates at low energy cost (Benkerrou and Ceccarelli, 2018). On the other hand, OccAB2, OccAB3, and OccAB4 mediate hydroxycinnamate (Smith et al., 2003), vanillate (Segura et al., 1999), and benzoate (Clark et al., 2002) transport, respectively. Being induced by limitation of metal ions, it may be presumed that OccAB1 may play a significant role in combating host-induced nutritional immunity and stress survival.

Diversity in *A. baumannii* OMP

Architecture, Expression, and Function

Besides the above three OMPs, a variety of proteins are identified in the outer membrane of *A. baumannii* with varied expressions and distinctive roles. One of the most abundant OMPs in *A. baumannii* is Omp33. Crystal structure of the protein revealed its function as a putative gated channel contributing to low permeability of the outer membrane (Abellón-Ruiz et al., 2018). Intracellular *A. baumannii* in the host cell expresses DcaP OMP in abundance. Crystallographic studies on DcaP revealed a trimeric porin structure with affinity to dicarboxylic acids and sulbactam (Bhamidimarri et al., 2019). The most abundant OMP under osmotic stress in *A. baumannii* is Omp38 (Jyothisri et al., 1999). Intracellular *A. baumannii* secretes Omp38, which localizes to the mitochondria stimulating the release of proapoptotic molecules such as cytochrome c and apoptosis-inducing factor (Choi et al., 2005). Oxidative stress in *A. baumannii* induces expression of AbuO, a homolog of Escherichia coli TolC OMP involved in resistance to amikacin, carbenicillin, ceftriaxone, meropenem, streptomycin, and tigecycline, and hospital-based disinfectants like benzalkonium chloride and chlorhexidine (Srinivasan et al., 2015). Under iron-limiting conditions, a 76-kDa iron-repressible OMP termed flhE was overexpressed in *A. baumannii* to facilitate uptake of xenosiderophores desferrioxoprogen, rhodotorulic acid and desferrioxamine B (Funahashi et al., 2012). Besides flhE, two other siderophore (acinetobactin) uptake proteins, BfnH and BauA are also elucidated in the outer membrane of *A. baumannii* (Sefid and Rasooli, 2012; Aghajani et al., 2019). The translation initiation factor EF-Tu, typically a cytoplasmic protein, is also found to localize in the outer membrane in *A. baumannii* (Dallo et al., 2012). Membrane associated EF-Tu binds to DsbA protein in the periplasm and assists in disulfide bonding during protein folding (Premkumar et al., 2014). Externally, EF-Tu binds to fibronectin thus mediating host cell adhesion (Dallo et al., 2012; Harvey et al., 2019). Decreased expression of a 33–36 kDa OMP (Clark, 1996; del Mar Tomás et al., 2005) and a 29 kDa (Jeong et al., 2009) is associated with imipenem resistance among *A. baumannii*. Serodiagnostic studies revealed an antigenic 34.4-kDa OMP specific to sera from *A. baumannii* infected patients (Islam et al., 2011). Upregulation of this protein along with downregulation of CarO and OprD was found to mediate imipenem resistance (Luo et al., 2011). The protein along with OmpA and TonB-dependant copper receptor was identified as fibronectin binding protein during infection (Smani et al., 2012). In *silico* exploration into the genome of *A. baumannii* revealed a nuclease (NucAb), BamA (Oma87), FilI, and TolB in the outer membrane as potential vaccine targets. Immunization with these recombinant proteins protected mice from lethal challenge with *A. baumannii* (Singh et al., 2014, 2016 and Singh et al., 2017; Garg et al., 2016; Song et al., 2018; Rasooli et al., 2020). In another effort toward developing a subunit vaccine against *A. baumannii* infections, a fusion protein of OmpK and Omp22 was synthesized which provided significantly greater protection against *A. baumannii* challenge in mice than those immunized with either of the two proteins individually (Huang et al., 2016; Guo et al., 2017; Guo S.J. et al., 2018).

CONCLUSION

One of the critical gaps in combating *A. baumannii* is deciphering its overall membrane permeability. Significant progress has been
made during the last decade in our understanding of how *A. baumannii* OMPs mediate antibiotic resistance and virulence in the host cells. Remarkable breakthroughs have also been made in understanding the regulatory mechanisms behind OMP expression and the mechanisms of antibiotic uptake. However, these efforts fall short in many aspects. The knowledge about *in vitro* or *in vivo* OMP assembly and folding dynamics in lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and hydrophobic loops in its structure, expression and purification of recombinant OmpA presents various hurdles. The solution of structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and hydrophobic loops in its structure, expression and purification of recombinant OmpA presents various hurdles. The solution of structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. The crystal structure of most studied *A. baumannii* OMP, OmpA is still elusive, although NLS domain structure has been resolved. Due to its complex structure and lipid bilayers is scarce. 

### AUTHOR CONTRIBUTIONS

SU, AS, and RP conceptualized the manuscript and contributed the ideas on the texts. SU and AS wrote the first draft of the manuscript. SU and RP edited the subsequent versions. All authors read and approved the final manuscript.

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.589234/full#supplementary-material

---

**REFERENCES**

Abbas, E., Goudarzi, H., Hashemi, A., Chirani, A. S., Ardebili, A., Goudarzi, M., et al. (2020). Decreased carO gene expression and OXA-type carbapenemases among extensively drug-resistant *Acinetobacter baumannii* strains isolated from burn patients in Tehran, Iran. *Acta Microb. Immunol. Hung.*. doi: 10.1556/030.2020.01138 [Epub ahead of print].

Abbott, I., Cerqueira, G. M., Bhiyani, S., and Peleg, A. Y. (2013). Carbapenem resistance in *Acinetobacter baumannii*: laboratory challenges, mechanistic insights and therapeutic strategies. *Expert Rev. Anti. Infect. Ther.* 11, 395–409. doi: 10.1586/eri.13.21

Abellón-Ruiz, J., Zahn, M., Basli, A., and van den Berg, B. (2018). Crystal structure of the *Acinetobacter baumannii* outer membrane protein Omp33. *Acta Crystallogr. D Struct. Biol.* 74(Pt 9), 852–860. doi: 10.1107/S205979831800904X

Agarwal, B., Karchikeyan, R., Gayathri, P., Rameshbabu, B., Ahmed, G., and Jagannadh, M. V. (2019). Studies on the mechanism of multidrug resistance of *Acinetobacter baumannii* by proteomic analysis of the outer membrane vesicles of the bacterium. *J. Proteins* 10, 1–15. doi: 10.1007/s42485-018-0001-4

Aghajani, Z., Rasooli, I., and Mousavi Gargari, S. L. (2019). Exploitation of two siderophore receptors, BauA and BfnH, for protection against *Acinetobacter baumannii* infection. *APMIS* 127, 753–763. doi: 10.1111/apm.12992

Alzubaidi, A. N., and Alkozai, Z. M. (2015). Immunogenic properties of outer membrane protein of *Acinetobacter baumannii* that loaded on chitosan nanoparticles. *Am. J. Bio Med.* 3, 59–74.

An, Z., Huang, X., Zheng, C., and Ding, W. (2019). *Acinetobacter baumannii* outer membrane protein A induces Hela cell autophagy via MAPK/INK signaling pathway. *Int. J. Med. Microbiol.* 309, 97–107. doi: 10.1016/j.ijmm.2018.12.004

An, Z., and Su, J. (2019). *Acinetobacter baumannii* outer membrane protein 34 elicits NLRP3 inflammasome activation via mitochondria-derived reactive oxygen species in RAW264.7 macrophages. *Microbes Infect.* 21, 143–153. doi: 10.1016/j.micinf.2018.10.005

Asadollahi, P., Akbari, M., Soroush, S., Taherikalani, M., Asadollahi, K., Sayehmiri, K., et al. (2012). Antimicrobial resistance patterns and their encoding genes among *Acinetobacter baumannii* strains isolated from burned patients. *Burns* 38, 1198–1203. doi: 10.1016/j.burns.2012.04.008

Asai, S., Umezawa, K., Iwasita, H., Ohshima, T., Ohashi, M., Sasaki, M., et al. (2014). An outbreak of blaOXA-51-like- and blaOXA-66-positive *Acinetobacter baumannii* ST208 in the emergency intensive care unit. *J. Med. Microbiol.* 63(Pt 11), 1517–1523. doi: 10.1099/jmm.0.077503-0

Bazmara, H., Rasooli, I., Jahangiri, A., Seifid, F., Astanee, S. D. A., and Payandeh, Z. (2019). Antigenic properties of iron regulated proteins in *Acinetobacter baumannii*: an in silico approach. *Int. J. Pept. Res. Ther.* 25, 205–213. doi: 10.1007/s10999-017-9665-6

Baylue, A., and Kumar, A. (2014). Incubation temperature, osmolality, and salicylate affect the expression of resistance-nodulation-division efflux pumps and outer membrane proteins in *Acinetobacter baumannii* ATCC19606T. *FEMS Microbiol. Lett.* 357, 136–143. doi: 10.1111/1574-6968.12530

Benkerrou, D., and Ceccarelli, M. (2018). Free energy calculations and molecular properties of substrate translocation through OccAB porins. *Phys. Chem. Chem. Phys.* 20, 8533–8546. doi: 10.1039/c7cp08299a

Benmahmod, A. B., Said, H. S., and Ibrahim, R. H. (2019). Prevalence and Mechanisms of Carbapenem Resistance among *Acinetobacter baumannii* clinical isolates in Egypt. *Microb. Drug Resist.* 25, 480–488. doi: 10.1016/j/mdr.2018.0141

Bhamidimarri, S. P., Zahn, M., Praipatapi, J. D., Schleberger, C., Söderholm, S., Hoover, J., et al. (2019). A multidisciplinary approach toward identification of antibiotic scaffolds for *Acinetobacter baumannii*. *Structure* 27, 268.e6–280.e6. doi: 10.1016/j.str.2018.10.021

Bhattacharyya, T., Sharma, A., Akhter, J., and Pathania, R. (2017). The small molecule ITR80287 restores the antibacterial activity of fluoroquinolones against multidrug-resistant *Acinetobacter baumannii* by efflux inhibition. *Int. J. Antimicrob. Agents* 50, 219–226. doi: 10.1016/j.ijantimicag.2017.03.005

Biswas, S., Mohammad, M. M., Patel, D. R., Movileanu, L., and van den Berg, B. (2007). Structural insight into OprD substrate specificity. *Nat. Struct. Mol. Biol.* 14, 1108–1109. doi: 10.1038/nsmb1304

Borneleit, P., and Kleber, H. P. (1991). “The outer membrane of acinetobacter: structure-function relationships,” in *The Biology of Acinetobacter, Federation of European Microbiological Societies Symposium Series, Vol. 57*, eds K. J. Towner, E. Bergogne-Bérézin, and C. A. Fewson (Boston, MA: Springer). doi: 10.1007/978-1-4899-3553-3_18

Bouvet, P. J., and Grimont, P. A. (1987). Identification and biotyping of clinical isolates of *Acinetobacter*. *Ann. Inst. Pasteur Microbiol.* 138, 569–578. doi: 10.1016/0769-2609(87)90042-1

Brossard, K. A., and Campagnari, A. A. (2012). The *Acinetobacter baumannii* biofilm-associated protein plays a role in adherence to human epithelial cells. *Infect. Immun.* 80, 228–233. doi: 10.1128/IAI.05913-11

---

**ACKNOWLEDGMENTS**

The authors read and approved the final manuscript. SU and AS wrote the first draft of the manuscript. SU and RP edited the subsequent versions. All authors read and approved the final manuscript.
Cardoso, J. P., Cayô, R., Girardello, R., and Gales, A. C. (2016). Diversity of mechanisms conferring resistance to \( \beta \)–lactams among OXA-23-producing Acinetobacter baumannii clones. *Diagn. Microbiol. Infect. Dis.* 85, 90–97. doi: 10.1016/j.diagmicrobio.2016.01.018

Catel-Ferreira, M., Coadou, G., Molle, V., Mugnier, P., Nordmann, P., Siroy, A., et al. (2011). Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of *Acinetobacter baumannii*. *J. Antimicrob. Chemother.* 66, 2053–2056. doi: 10.1093/jac/dkr267

Catel-Ferreira, M., Nehmê, R., Molle, V., Aranda, J., Bouffartigues, E., Chevalier, S., et al. (2012). Deciphering the function of the outer membrane protein OprD homologue of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 56, 3826–3832. doi: 10.1128/AAC.00622-11

Catel-Ferreira, M., Martí, S., Guillón, L., Jara, L., Coadou, G., Molle, V., et al. (2016). The outer membrane porin OmpW of *Acinetobacter baumannii* is involved in iron uptake and colistin binding. *FEMS Lett.* 590, 224–231. doi: 10.1002/1873-9421.20150

Choi, C. H., Hyun, S. H., Kim, J., Lee, Y. C., Seol, S. Y., Cho, D. T., et al. (2008a). Nuclear translocation and DNaseI-like enzymatic activity of *Acinetobacter baumannii* outer membrane protein A. *FEMS Microbiol. Lett.* 288, 62–67. doi: 10.1111/j.1574-6968.2008.01323.x

Choi, C. H., Hyun, S. H., Lee, J. Y., Lee, J. S., Kim, S. A., et al. (2008b). *Acinetobacter baumannii* outer membrane protein A targets the nucleus and induces cytotoxicity. *Cell Microbiol.* 10, 309–319. doi: 10.1111/j.1462-5822.2007.01041.x

Choi, C. H., Lee, J. S., Lee, Y. C., Park, T. I., and Lee, J. C. (2008c). *Acinetobacter baumannii* invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. *J. Microbiol. Biochem.** 8:216. doi: 10.11471/2180-8-216

Choi, C. H., Lee, E. Y., Lee, Y. C., Park, T. I., Kim, H. J., Hyun, S. H., et al. (2005). Outer membrane protein 38 of *Acinetobacter baumannii* localizes to the mitochondria and induces apoptosis of epithelial cells. *Cell Microbiol.* 7, 1127–1138. doi: 10.1111/j.1462-5822.2005.00538.x

Choi, C. H., Lee, J. S., and Lee, J. C. (2007). “A versatile role of outer membrane protein a in pathogenesis of *Acinetobacter baumannii*,” in *Proceedings of the Microbiological Society of Korea Conference* (South Korea: The Microbiological Society of Korea), 107–108.

Clark, R. B. (1996). Impenem resistance among *Acinetobacter baumannii*: association with reduced expression of a 33-36 kDa outer membrane protein. *J. Antimicrob. Chemother.* 38, 245–251. doi: 10.1093/jac/38.2.245

Clark, T. J., Momany, C., and Neidle, E. L. (2002). The benPK operon, proposed to play a role in transport, is part of a regulon for benzoate catabolism in *Acinetobacter sp.* strain ADP1. *Microbiology* 148( Pt 4), 1213–1223. doi: 10.1099/00221287-148-4-1213

Confer, A. W., and Ayalew, S. (2013). The OmpA family of proteins: roles in bacterial pathogenesis and immunity. *Vet. Microbiol.* 163, 207–222. doi: 10.1016/j.vetmic.2012.08.019

Costa, R. F., Cayô, R., Matos, A. P., Girardello, R., Martins, W., Carrara-Marroni, F. E., et al. (2019). Temporal evolution of *Acinetobacter baumannii* ST107 clone: conversion of blaOXA-143 into blaOXA-231 coupled with mobilization of ISAb1 upstream occAB1. *Res. Microbiol.* 170, 53–59. doi: 10.1016/j.resmic.2018.07.001

Cuenca, F. P., Fascul, A., Martinez, L. M., Conejo, M. C., and Perea, E. J. (2003). Evaluation of SDS-polyacrylamide gel systems for the study of outer membrane protein profiles of clinical strains of *Acinetobacter baumannii*. *J. Basic Microbiol.* 43, 194–201. doi: 10.1002/1520-5749(2003)120:1<194::AID-JBM13>3.0.CO;2-1

Cuenca, F. P., Smani, Y., Gómez-Sánchez, M. C., Docobo-Pérez, F., Caballero-Costa, R. F., Cayô, R., Matos, A. P., Girardello, R., Martins, W., et al. (2012). Association of *Acinetobacter baumannii* EF-Tu with cell surface, outer membrane vesicles, and fibrinogen. *ScientificWorldJournal* 2012:128705. doi: 10.1100/2012/128705

Darbandian, P., and Sefid, F. (2016). Evaluation of OMP A (Outer Membrane Protein A) linear and conformational epitopes in *Acinetobacter baumannii*. *Int. J. Adv. Biotechnol. Res.* 7:3.
Hancock, R. E., and Brinkman, F. S. (2002). Function of Pseudomonas porins in uptake and eflux. *Annu. Rev. Microbiol.* 56, 17–38. doi: 10.1146/annurev.micro.56.021302.160310

Hanson, K. G., Kale, V. C., and Desai, A. J. (1994). The possible involvement of cell surface and outer membrane proteins of *Acinetobacter* sp. A3 in crude oil degradation. *FEMS Microbiol. Lett.* 122, 275–279. doi: 10.1111/j.1574-6968.1994.tb07180.x

Harding, C. M., Hennon, S. W., and Feldman, M. F. (2018). Uncovering the mechanisms of *Acinetobacter baumannii* virulence. *Nat. Rev. Microbiol.* 16, 91–102. doi: 10.1038/nrmicro.2017.148

Harvey, K. L., Jarocki, V. M., Charles, I. G., and Djordjevic, S. P. (2019). The diverse roles of OmpA and OmpC in Acinetobacter baumannii. *Front. Microbiol.* 10:2351. doi: 10.3389/fmicb.2019.02351

Hood, M. I., Jacobs, A. C., Sayood, K., Dunman, P. M., and Skaar, E. P. (2010). *Acinetobacter baumannii* bacteria increases tolerance to antibiotics in response to monovalent cations. *Antimicrob. Agents Chemother.* 54, 1029–1041. doi: 10.1128/AAC.00963-09

Huang, W., Yao, Y., Wang, S., Xia, Y., Xiong, L., et al. (2016). Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant *Acinetobacter baumannii*. *Sci. Rep.* 6:20724. doi: 10.1038/srep20724

Hwa, W. E., Subramaniam, G., Mansor, B. M., Yan, O. S., Gracie, Anbazhagan, D., et al. (2010). Iron regulated outer membrane proteins (IROMPs) as potential targets against carbapenem-resistant *Acinetobacter* spp. isolated from a Medical Centre in Malaysia. *Indian J. Med. Res.* 131, 578–583

Islam, A. H., Singh, K. K., and Ismail, A. (2011). Demonstration of an outer membrane protein that is antigenically specific for *Acinetobacter baumannii*. *Diagn. Microbiol. Infect. Dis.* 69, 38–44. doi: 10.1016/j.diagmicrobio.2010.09.008

Iyer, R., Moussa, S. H., Durand-Réville, T. F., Tommasi, R., and Miller, A. (2018). *OmpA* is a selective antibiotic permeant porin. *ACS Infect. Dis.* 4, 373–381. doi: 10.1021/acsinfectd.7b00168

Jahangiri, A., Rasooli, I., Owlia, P., Fooladi, A. A., and Salimian, J. (2017). In silico design of an immunogen against *Acinetobacter baumannii* based on a novel model for native structure of outer membrane protein A. *Microb. Pathog.* 105, 201–210. doi: 10.1016/j.micpath.2017.02.028

Jeong, H. W., Cheong, H. J., Kim, W. J., Kim, M. J., Song, K. J., Song, J. W., et al. (2009). Loss of the 29-kilodalton outer membrane protein in the presence of OXA-51-like enzymes in *Acinetobacter baumannii* is associated with decreased imipenem susceptibility. *Microb. Drug Resist.* 15, 151–158. doi: 10.1089/mdr.2009.0828

Jin, J. S., Kwon, S. O., Moon, D. C., Gurung, M., Lee, J. H., Kim, S. I., et al. (2011). *Acinetobacter baumannii* secretes cytotoxic outer membrane protein A via outer membrane vesicles. *PLoS One* 6:e17027. doi: 10.1371/journal.pone.0017027

Jyothiari, K., Deepak, V., and Rajeswari, M. R. (1999). Purification and characterization of a major 40 kDa outer membrane protein of *Acinetobacter baumannii*. *FEBS Lett.* 443, 57–60. doi: 10.1016/S0014-5793(98)01679-2

Khorsi, K., Messai, Y., Ammari, H., Hamidi, M., and Bakour, R. (2018). *ISAba36* inserted into the outer membrane protein gene carO and associated with the carbapenemase gene blaOXA-23. *Biochem. Pharmacol.* 74, 86–97. doi: 10.1016/j.bcp.2007.02.012

Khorsi, K., Messai, Y., Ammari, H., Hamidi, M., and Bakour, R. (2018). *ISAba36* inserted into the outer membrane protein gene carO and associated with the carbapenemase gene blaOXA-23. *Biochem. Pharmacol.* 74, 86–97. doi: 10.1016/j.bcp.2007.02.012

Kim, B. R., Yang, E. K., Kim, D. Y., Kim, S. H., Moon, D. C., Lee, J. H., et al. (2012). Anti-tumor activity of *Acinetobacter baumannii* outer membrane protein A on dendritic cell-based immunotherapy against murine melanoma. *J. Microbiol.* 46, 221–227. doi: 10.11217/microbiol.46.2012-008-0052-z

Lee, J. S., Lee, J. C., Lee, C. M., Jung, I. D., Jeong, Y. I., Seong, E. Y., et al. (2007). Outer membrane protein A of *Acinetobacter baumannii* induces differentiation of CD4+ T cells toward a Th1 polarizing phenotype through the activation of dendritic cells. *Biochim. Biophys. Acta* 1774, 86–97. doi: 10.1016/j.bjba.2007.02.012

Limansky, A. S., Mussi, M. A., and Viale, A. M. (2011). A novel insertion sequence, ISAba10, inserted into ISAba1 adjacent to the blaOXA-23 gene and disrupting the outer membrane protein gene carO in *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 55, 361–363. doi: 10.1128/AAC.01672-09

Li, Q., Li, Z., Qu, Y., Li, H., Xing, J., and Hu, D. (2015). A study of outer membrane protein and molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii*. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 27, 611–615. doi: 10.3760/cma.j.issn.2095-4352.2015.07.014

Lin, M. S., Mucci, M. A., and Viale, A. M. (2002). Loss of a 29-kilodalton outer membrane protein in *Acinetobacter baumannii* is associated with imipenem resistance. *J. Clin. Microbiol.* 40, 4776–4778. doi: 10.1128/JCM.40.11.4776-4778.2002

Lin, M. F., and Lan, C. Y. (2014). Antimicrobial resistance in *Acinetobacter baumannii*: From bench to bedside. *World J. Clin. Cases* 2, 787–814. doi: 10.12998/wjcc.v2.i2.787

Lin, M. F., Lin, Y. Y., and Lan, C. Y. (2020). Characterization of biofilm development in different strains of *Acinetobacter baumannii* and the effects of chemical compounds on biofilm formation. *PeerJ* e49020. doi: 10.7717/peerj.9020

Lin, M. F., Tsi, P. W., Chen, J. Y., Lin, Y. Y., and Lan, C. Y. (2015). OmpA binding mediates the effect of an antimicrobial peptide LL-37 on *Acinetobacter baumannii*. *PLoS One* 10:e0141107. doi: 10.1371/journal.pone.0141107

Liu, M. L., Sook, P. C., Ling, S. R., Kuo, H. Y., Tang, C. Y., and Chang, K. C. (2014). The sensor kinase BfmS mediates virulence in *Acinetobacter baumannii*. *Microb. Immunol.* 47, 275–281. doi: 10.1016/j.mim.2012.12.004
Liu, L., Cui, Y., Zheng, B., Jiang, S., Wu, Q., Wei, L., Li, J., and Ying, C. (2011). Efflux pump overexpression in conjunction with alteration of outer membrane protein may induce Acinetobacter baumannii resistant to imipenem. Chemotherapy 57, 77–84. doi: 10.1159/000323620

McConnell, M. J., Domínguez-Herrera, J., Smani, Y., López-Rojas, R., Docobo-Pérez, F., and Pachón, J. (2011). Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect. Immun. 79, 518–526. doi: 10.1128/IAI.00741-10

Nan, L. I., Zhang, H. J., Wang, Y., Meng, Q. I., Guo, W. X., Wang, Z., et al. (2018). Outer membrane protein involved in carbapenem-resistant Acinetobacter baumannii as a virulence factor. Anaerobe 51, 1–8. doi: 10.1016/j.anaerobe.2017.08.007

Moon, D. C., Choi, C. H., Lee, J. H., Choi, C. W., Kim, H. Y., Park, J. S., et al. (2012). Structure of the Acinetobacter baumannii outer membrane protein Omp33-36 porin is a virulence factor. J. Biomed. Sci. 19, 396–401. doi: 10.1186/1423-0127-19-396

Morrán-Barrio, J., Cameranesi, M. M., Relling, V., Limansky, A. S., Brambilla, L., and Viale, A. M. (2017). The Acinetobacter outer membrane contains multiple specific channels for carbapenem β-lactams as revealed by kinetic characterization analyses of imipenem permeation into Acinetobacter baumannii. PLoS One 12, e017376. doi: 10.1371/journal.pone.017376-16

Mussi, M. A., Limansky, A. S., Relling, V., Rasavi, P., Arakaki, A., Actis, L. A., et al. (2011). Horizontal gene transfer and assortative recombination within the Acinetobacter baumannii clinical population provide genetic diversity at the single carO gene, encoding a major outer membrane protein channel. J. Bacteriol. 193, 4736–4748. doi: 10.1128/JB.01533-10

Nitzan, Y., Pechatnikov, I., Bar-El, D., and Weder, H. (1999). Isolation and characterization of heat-modifiable proteins from the outer membrane of Porphyromonas asaccharolytica and Acinetobacter baumannii. Anaerobe 5, 43–50. doi: 10.1006/anac.1998.0181

Park, J. S., Lee, W. C., Choi, S., Yeo, K. J., Song, J. H., Han, Y. H., et al. (2011). Overexpression, purification, crystallization and preliminary X-ray crystalllographic analysis of the periplasmic domain of outer membrane protein A from Acinetobacter baumannii. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67(PT 12), 1531–1533. doi: 10.1107/S1744309111038401

Pajand, O., Rezaee, M. A., Naheiri, M. R., Mahdian, R., Aghazadeh, M., Soroush, M. H., et al. (2013). Study of the carbapenem resistance mechanisms in clinical isolates of Acinetobacter baumannii: comparison of burn and non-burn strains. Burns 39, 1414–1419. doi: 10.1016/j.burns.2013.03.024

Poli, Z., Speranza, A., Carraro, A., Niccolai, F., Brancaccio, L., and Falagari, G. (2017). Overproduction of outer membrane protein Omp33-36 porin in carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 72, 2856–2864. doi: 10.1093/jac/dkx118
Sharma, A., Dubey, V., Sharma, R., Devnath, K., Gupta, V. K., Akhter, J., et al. (2019). Functional exposed amino acids of CarO analysis as a potential vaccine candidate in Acinetobacter baumannii. *Int. J. Pept. Res. Thera*. 26, 1185–1197. doi: 10.1007/s10998-019-00923-2

Tsai, Y. K., Liou, C. H., Lin, J. C., Fung, C. P., Chang, F. Y., and Siu, L. K. (2020). Effects of different resistance mechanisms on antimicrobial resistance in Acinetobacter baumannii: a strategic system for screening and activity testing of new antibiotics. *Int. J. Antimicrob. Agents*. 55:105918. doi: 10.1016/j.ijantimicag.2020.105918

van der Kolk, J. H., Endimiani, A., Graubner, C., Gerber, V., and Perreten, V. (2019). Acinetobacter in veterinary medicine, with an emphasis on Acinetobacter baumannii. *J. Glob. Antimicrob. Resist*. 16, 59–71. doi: 10.1016/j.jgar.2018.08.011

Vashist, J., Tiwari, V., Kapil, A., and Rajeswari, M. R. (2010). Quantitative profiling and identification of outer membrane proteins of beta-lactam resistant strain of *Acinetobacter baumannii*. *Proteome Res*. 9, 1121–1128. doi: 10.1016/prr9011188

Viale, A. M., and Evans, B. A. (2020). Microevolution in the major outer membrane protein OmpA of *Acinetobacter baumannii*. *Microb. Genom*. 6:e000381. doi: 10.1099/mgen.0.000381

Vila-Farrés, X., Parra-Millán, R., Sánchez-Encinales, V., Varese, M., Ayerbe-Algaba, R., Bayón, N., et al. (2017). Combating virulence of Gram-negative bacilli by OmpA inhibition. *Sci. Rep*. 7, 14683. doi: 10.1038/s41598-017-14792-y

Walzer, G., Rosenberg, E., and Ron, E. Z. (2006). The *Acinetobacter* protein Hfq plays an important role in bacterial physiology. *J. Biol. Chem.* 281, 29, 2122–2128. doi: 10.1093/bioinformatics/bt655

Wang, T., Yuan, Q., and Ling, B. (2015). Analysis of the expression of the outer membrane protein in carbapenem-resistant *Acinetobacter baumannii*. *Int. J. Lab. Med*. 2015, 2295–2296.

Weiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J., et al. (2016). Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014. *Infect. Control Hosp. Epidemiol*. 37, 1288–1301. doi: 10.1017/ice.2016.174

World Health Organization [WHO] (2017). *Global Priority list of Antibiotic-Resistant Bacteria to Guide Research, Discovery and Development of New Antibiotics*. Geneva: WHO.

Wu, X., Chavez, J. D., Schweppe, D. K., Zheng, C., Weisbrod, C. R., Eng, J. K., et al. (2016). In vivo protein interaction network analysis reveals porin-localized antibiotic inactivation in *Acinetobacter baumannii* strain AB5075. *Nat. Commun*. 7:13414. doi: 10.1038/ncomms13414

Yang, H., Huang, L., Barnie, P. A., Su, Z., Mi, Z., Chen, J., et al. (2015). Characterization and distribution of drug resistance associated β-lactamase, membrane porin and efflux pump genes in MDR A. baumannii isolated from Zhenjiang, China. *Int. J. Clin. Exp. Med*. 8, 15393–15402.

Yun, S. H., Choi, C. W., Park, S. H., Lee, J. C., Leem, S. H., Choi, J. S., et al. (2008). Proteomic analysis of outer membrane proteins from *Acinetobacter baumannii* DU202 in tetracycline stress condition. *J. Microbiol*. 46, 720–727. doi: 10.1007/s12275-008-0202-3

Yun, S. H., Park, E. C., Lee, Y. S., Lee, H., Choi, C. W., Yi, Y. S., et al. (2018). Antibiotic treatment modulates protein components of cytotoxic outer membrane vesicles of multidrug-resistant clinical strain, *Acinetobacter baumannii* DU202. *Clin. Proteomics* 15:28. doi: 10.1186/s12275-014-0094-2

Zahn, M., Bhamidimarri, S. P., Baslé, A., Winterhalter, M., and van den Berg, B. (2016). Structural insights into outer membrane permeability of *Acinetobacter baumannii*. *Structure*. 24, 221–231. doi: 10.1016/j.str.2015.12.009

Zahn, M., D’Agostino, T., Eren, E., Baslé, A., Ceccarelli, M., and van den Berg, B. (2015). Small-molecule transport by CarO, an abundant eight-stranded β-barrel outer membrane protein from *Acinetobacter baumannii*. *J. Mol. Biol*. 427, 2329–2339. doi: 10.1016/j.jmb.2015.03.016

Zhao, S. Y., Jiang, D. Y., Xu, P. C., Zhang, Y. K., Shi, H. F., Cao, H. L., et al. (2015). An investigation of drug-resistant *Acinetobacter baumannii* infections
in a comprehensive hospital of East China. *Ann. Clin. Microbiol. Antimicrob.* 14:7. doi: 10.1186/s12941-015-0066-4

Zhou, H., Yao, Y., Zhu, B., Ren, D., Yang, Q., Fu, Y., et al. (2019). Risk factors for acquisition and mortality of multidrug-resistant *Acinetobacter baumannii* bacteremia: a retrospective study from a Chinese hospital. *Medicine* 98:e14937. doi: 10.1097/MD.00000000000014937

Zhu, L. J., Chen, X. Y., and Hou, P. F. (2019). Mutation of CarO participates in drug resistance in imipenem-resistant *Acinetobacter baumannii*. *J. Clin. Lab. Anal.* 33:e22976. doi: 10.1002/jcla.22976

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Uppalapati, Sett and Pathania. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**